Annual screening for prostate cancer did not reduce mortality from prostate cancer

August 2009
Evidence Based Medicine;Aug2009, Vol. 14 Issue 4, p104
Academic Journal
The article examines the effectiveness of annual screening for prostate cancer in reducing mortality rate. Based on randomised controlled trials conducted to 76,693 men ranging from 55 to 74-years-old was considered to be a positive result. Meanwhile, the result shows that the incidence and mortality from prostate cancer has detected a 20% reduction in prostate cancer mortality.


Related Articles

  • Annual screening for prostate cancer did not reduce mortality from prostate cancer. Canfield, Steven E. // ACP Journal Club;6/23/2009, Vol. 150 Issue 6, p2 

    The article discusses annual screening for prostate cancer in men in the age group of 55 to 74 years old. Randomized controlled trial was conducted on 76, 693 men in ten centers in the U.S. The intervention, outcomes and participants follow-up of the trial are discussed. It was concluded that...

  • In Brief.  // Urology Times;2/1/2005, Vol. 33 Issue 2, p5 

    Reports developments on urology. Increase in the risk of prostate cancer patients on androgen-deprivation therapy to bone fractures; Relation between the alpha-blocker tamsulosin and a new small pupil syndrome known as intraoperative floppy iris syndrome; Decrease in the mortality rate of...

  • Does testing for prostate-specific antigen contribute to declining prostate cancer mortality? Di Matteo, L.; Di Matteo, R. // European Journal of Health Economics;Dec2005, Vol. 6 Issue 4, p298 

    Key variables associated with prostate cancer mortality were examined using Canadian province level time-series data over the period 1979–1999 in a multiple regression framework. The key variables driving the prostate cancer mortality rate are per capita income, per capita number of...

  • Malignant Neoplasms of Male Genital Organs (C60-C63) in the Os iek-Baranja County, Croatia. Milas, Josip; Samardžić, Senka; Milas, Krešimir // Collegium Antropologicum;2014, Vol. 38 Issue 3, p949 

    Cancers of male genital organs (C60-C63) and in particular, prostate cancer, represent one of the most frequent cancer groups among males in economically developed countries and growing cancer group in developing countries. The Institute of Public Health of the Osijek-Baranja County in...

  • Pre-treatment PSA velocity predicts recurrence risk. Bankhead, Charles // Urology Times;8/15/2004, Vol. 32 Issue 12, p1 

    Reports that a preoperative rise in serum prostate specific antigen of >2.0 ng⁄ml predicts an increased mortality risk in patients with localized prostate cancer undergoing a radical prostatectomy and might identify men who require additional therapy in Boston, as concluded by...

  • Mortality rate from early prostate cancer increased 3-fold after 15 years following the diagnosis. Johansson, J.E. // ACP Journal Club;Jan/Feb2005, Vol. 142 Issue 1, p24 

    The article reports that mortality rate from early prostate cancer increased 3-fold after 15 years following the diagnosis. Progression of disease, and death from prostate cancer and all-cause mortality. Multivariable analysis showed that the risk for death from prostate cancer was greater after...

  • Early radical prostatectomy improves disease-specific but not overall survival. Cunningham, David C.; Newton, Warren P. // Journal of Family Practice;Jan2003, Vol. 52 Issue 1, p22 

    This article discusses research done on the effectiveness of radical prostatectomy as compared with watchful waiting in patients with early prostate cancer. It references the study "A Randomized Trial Comparing Radical Prostatectomy With Watchful Waiting in Early Prostate Cancer," by L....

  • Prostate-Cancer Mortality at 11 Years of Follow-up. Schr�der, Fritz H.; Hugosson, Jonas; Roobol, Monique J.; Tammela, Teuvo L.J.; Ciatto, Stefano; Nelen, Vera; Kwiatkowski, Maciej; Lujan, Marcos; Lilja, Hans; Zappa, Marco; Denis, Louis J.; Recker, Franz; P�ez, Alvaro; M��tt�nen, Liisa; Bangma, Chris H.; Aus, Gunnar; Carlsson, Sigrid; Villers, Arnauld; Rebillard, Xavier; van der Kwast, Theodorus // New England Journal of Medicine;3/15/2012, Vol. 366 Issue 11, p981 

    Background: Several trials evaluating the effect of prostate-specific antigen (PSA) testing on prostate-cancer mortality have shown conflicting results. We updated prostate-cancer mortality in the European Randomized Study of Screening for Prostate Cancer with 2 additional years of follow-up....

  • Prostate-Specific Antigen Screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer–Rotterdam. Wever, Elisabeth M.; Draisma, Gerrit; Heijnsdijk, Eveline A. M.; Roobol, Monique J.; Boer, Rob; Otto, Suzie J.; De Koning, Harry J. // JNCI: Journal of the National Cancer Institute;3/3/2010, Vol. 102 Issue 5, p352 

    Dissemination of prostate-specific antigen (PSA) testing in the United States coincided with an increasing incidence of prostate cancer, a shift to earlier stage disease at diagnosis, and decreasing prostate cancer mortality. We compared PSA screening performance with respect to prostate cancer...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics